Mouri S, Thabut D
Hepatogastroenterology Department, La Pitie-Salpetriere Hospital, AP-HP, Sorbonne Universite, Paris, France.
Brain-Liver Pitie-Salpetriere Study Group (BLIPS), Paris, France.
United European Gastroenterol J. 2025 Jul;13(6):851-852. doi: 10.1002/ueg2.70028. Epub 2025 May 2.
Covert hepatic encephalopathy (CHE) is a subtle yet significant neurological complication of liver diseases, especially in patients with cirrhosis. Although it lacks overt clinical signs, CHE severely impacts quality of life, increases accident risks, and has serious prognostic implications. It is characterized by neurocognitive symptoms detectable only through specialized neuropsychometric tests. CHE affects 30%-80% of cirrhotic patients and represents the early stage of hepatic encephalopathy, which is a predictor of mortality. Early diagnosis is essential to improve patient outcomes. The Psychometric Hepatic Encephalopathy Score (PHES) is the gold standard for diagnosing CHE, but it is time-consuming and requires specialized training. Other tests, like the Animal Naming Test (ANT), are simpler and more practical for screening minimal hepatic encephalopathy (MHE), though they lack specificity. The Stroop test shows promise as a quicker and reliable diagnostic tool, but still has limitations. Recent innovations include a smartphone-based self-screening method developed by Dobbermann et al., combining three digital tests: the Tip Test, Number Connection Test, and Modified Stroop Test. This approach correlates well with PHES, is independent of language skills, and is accessible for a diverse patient population, including those with color vision deficiencies. This tool offers a rapid and reliable way to screen for CHE even in home settings, potentially improving early detection and intervention. In conclusion, CHE is an underrecognized but critical condition that requires greater clinical attention. Current diagnostic tools have limitations, highlighting the need for more effective, practical methods. A multidisciplinary approach involving hepatologists, neurologists, and neuropsychologists is crucial to improve the diagnosis and management of CHE, ultimately enhancing patient outcomes.
隐匿性肝性脑病(CHE)是肝脏疾病中一种隐匿但严重的神经并发症,在肝硬化患者中尤为常见。尽管它缺乏明显的临床症状,但CHE严重影响生活质量,增加事故风险,并具有严重的预后意义。其特征是只有通过专门的神经心理测试才能检测到的神经认知症状。CHE影响30%-80%的肝硬化患者,是肝性脑病的早期阶段,也是死亡率的一个预测指标。早期诊断对于改善患者预后至关重要。心理测量肝性脑病评分(PHES)是诊断CHE的金标准,但它耗时且需要专门培训。其他测试,如动物命名测试(ANT),对于筛查轻微肝性脑病(MHE)更简单、更实用,尽管它们缺乏特异性。Stroop测试有望成为一种更快、更可靠的诊断工具,但仍有局限性。最近的创新包括Dobbermann等人开发的一种基于智能手机的自我筛查方法,该方法结合了三项数字测试:指尖测试、数字连接测试和改良Stroop测试。这种方法与PHES相关性良好,独立于语言技能,并且适用于包括色盲患者在内的不同患者群体。即使在家庭环境中,这种工具也提供了一种快速、可靠的CHE筛查方法,有可能改善早期检测和干预。总之,CHE是一种未被充分认识但至关重要的疾病,需要更多的临床关注。目前的诊断工具存在局限性,凸显了对更有效、实用方法的需求。肝病学家、神经学家和神经心理学家的多学科方法对于改善CHE的诊断和管理至关重要,最终可提高患者的治疗效果。